The ICD market in cardiac rhythm management has been one of the medical device industry's fastest growing markets over the past several years. Yet for all its success, only about 20% of the patients who could benefit from an ICD get one. Why is that? Officials from Cameron Health argue that the complexity of current devices frustrate many cardiologists and force them to hand patients over to electrophysiologists, a move that they often resist. Now, Cameron hopes to blow open the untapped portion of the market with a device that is simpler to use, one that cardiologists will feel comfortable implanting.
By David Cassak
For most medical device start-ups, a successful entrée into the marketplace rests on making their technology a little bit better—a...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
Rapport Therapeutics CEO discusses the company's novel approach to AMPA modulation and why strategic externalization from J&J is accelerating neuroscience innovation.
Merck KGaA's Emre Ozcan outlines the company's systematic approach to integrating digital solutions across the care continuum in specialty pharmaceuticals, moving from technology-first to patient-need-first strategies.
ReproNovo's $65m Series A targets the $1.5bn male infertility market with the first potential oral therapy. Its first-in-class approach to underserved conditions like adenomyosis positions it as an attractive acquisition target in fertility's concentrated market.
Axelyf raises $2.6m seed round for lipid nanoparticle delivery platform on heels of end to US federal support for mRNA vaccines.
Tevard Biosciences CEO Daniel Fischer discusses how engineered suppressor tRNAs overcome nonsense mutations, restoring full-length protein production to treat rare genetic diseases like Dravet syndrome.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
